SUPNSupernus Pharmaceuticals Inc

Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.

Biogen climbs 11.5% YTD as new drugs, pipeline progress and M&A activity fuel confidence in Biogen???s multiyear turnaround.

Key PointsQuantedge Capital exited 89,600 shares of Supernus Pharmaceuticals in the first quarter, with an estimated trade size of $4.56 million based on quarterly average prices...

Supernus Pharmaceuticals (NASDAQ:SUPN) reported first-quarter 2026 results that management said reflected "a strong start to the year," driven by growth across its key brands and collaboration-related revenue. Chief Executive Officer Jack Khattar highlighted a 56% year-over-year increase in combined...

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Supernus (SUPN) delivered earnings and revenue surprises of +110.71% and +10.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) issued its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter...

Pictet Asset Management Holding SA cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent Form...

Bausch (BHC) delivered earnings and revenue surprises of -3.11% and +4.72%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?